CN102245607B - 吗啉代嘌呤衍生物 - Google Patents

吗啉代嘌呤衍生物 Download PDF

Info

Publication number
CN102245607B
CN102245607B CN200980151585.4A CN200980151585A CN102245607B CN 102245607 B CN102245607 B CN 102245607B CN 200980151585 A CN200980151585 A CN 200980151585A CN 102245607 B CN102245607 B CN 102245607B
Authority
CN
China
Prior art keywords
compound
morpholin
group
purin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980151585.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102245607A (zh
Inventor
中山清
杉田和幸
濑户口正树
冨永裕一
斎藤正规
小田桐高志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN102245607A publication Critical patent/CN102245607A/zh
Application granted granted Critical
Publication of CN102245607B publication Critical patent/CN102245607B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980151585.4A 2008-10-14 2009-10-13 吗啉代嘌呤衍生物 Expired - Fee Related CN102245607B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-264797 2008-10-14
JP2008264797 2008-10-14
JP2009121690 2009-05-20
JP2009-121690 2009-05-20
PCT/JP2009/067738 WO2010044401A1 (ja) 2008-10-14 2009-10-13 モルホリノプリン誘導体

Publications (2)

Publication Number Publication Date
CN102245607A CN102245607A (zh) 2011-11-16
CN102245607B true CN102245607B (zh) 2014-07-02

Family

ID=42106564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980151585.4A Expired - Fee Related CN102245607B (zh) 2008-10-14 2009-10-13 吗啉代嘌呤衍生物

Country Status (21)

Country Link
US (2) US8097622B2 (enExample)
EP (1) EP2336132B1 (enExample)
JP (1) JP5090423B2 (enExample)
KR (1) KR101614976B1 (enExample)
CN (1) CN102245607B (enExample)
AU (1) AU2009304789B2 (enExample)
BR (1) BRPI0920199A2 (enExample)
CA (1) CA2740471C (enExample)
CO (1) CO6362009A2 (enExample)
DK (1) DK2336132T3 (enExample)
ES (1) ES2452541T3 (enExample)
IL (1) IL212278A (enExample)
MX (1) MX2011003490A (enExample)
MY (1) MY156456A (enExample)
NZ (1) NZ592761A (enExample)
PL (1) PL2336132T3 (enExample)
PT (1) PT2336132E (enExample)
RU (1) RU2490269C2 (enExample)
TW (1) TWI378933B (enExample)
WO (1) WO2010044401A1 (enExample)
ZA (1) ZA201102449B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
BR112012011188A2 (pt) * 2009-11-12 2021-06-29 F.Hoffmann - La Roche Ag ''composto,composição farmacêutica e uso de um composto"
CN102260263A (zh) * 2010-05-26 2011-11-30 四川大学 一类二苯胺基嘌呤衍生物及制备方法和医药用途
EP2593455B1 (en) 2010-07-14 2015-03-18 F.Hoffmann-La Roche Ag Purine compounds selective for i3 p110 delta, and methods of use
SG10201510347QA (en) 2010-12-16 2016-01-28 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
US9334271B2 (en) 2011-10-28 2016-05-10 Novarits Ag Purine derivatives and their use in the treatment of disease
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
WO2014185368A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 ５－｛８－［（３ｒ）－４－アセチル－３－メチルピペラジン－１－イル］－６－モルホリン－４－イル－９－（２，２，２－トリフルオロエチル）－９ｈ－プリン－２－イル｝ピリミジン－２－アミン、およびその薬理上許容される塩の新規な結晶、およびその製造方法
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
KR102369925B1 (ko) * 2013-10-04 2022-03-03 우니베르시태트 바젤 구조적으로 제한된 PI3K 및 mTOR 억제제
MY185268A (en) 2015-03-30 2021-04-30 Daiichi Sankyo Co Ltd Pyrazole derivative useful as pi3k inhibitor
US10765681B2 (en) 2016-02-05 2020-09-08 Academia Sinica Purine compounds possessing anticancer activity
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US11208442B2 (en) 2016-12-02 2021-12-28 Daiichi Sankyo Company, Limited Endo-beta-N-acetylglucosaminidase
EP3360865A1 (en) 2017-02-13 2018-08-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272
TWI837231B (zh) 2018-11-29 2024-04-01 日商第一三共股份有限公司 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途
CN113368114B (zh) * 2020-03-10 2022-04-22 四川大学 一种吗啉嘧啶类化合物的抗肿瘤应用
JP2024511996A (ja) * 2021-03-17 2024-03-18 タンゴ セラピューティクス， インコーポレイテッド 抗がん剤としてのプリン誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3810017B2 (ja) 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
ATE503743T1 (de) 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate
WO2002088112A1 (en) 2001-04-27 2002-11-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
ES2389253T3 (es) 2002-10-25 2012-10-24 Zenyaku Kogyo Kabushiki Kaisha Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
KR101052482B1 (ko) 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AU2006302148B2 (en) 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EA016945B1 (ru) 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
DK2024372T3 (da) 2006-04-26 2010-09-20 Hoffmann La Roche Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
CA2650290C (en) 2006-04-26 2015-11-17 Genentech, Inc. Pharmaceutical compounds
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
GB0611152D0 (en) 2006-06-06 2006-07-19 Ucb Sa Therapeutic agents
PL2050749T3 (pl) 2006-08-08 2018-03-30 Chugai Seiyaku Kabushiki Kaisha Pochodna pirymidyny jako inhibitor pi3k i jej zastosowanie
WO2008023161A1 (en) 2006-08-23 2008-02-28 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008023180A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
JP2010503651A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性障害の治療用のＰＩ３Ｋ及びｍＴＯＲ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−フェニルピリミジン誘導体
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032028A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
ES2571028T3 (es) 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
ES2381895T3 (es) 2007-02-06 2012-06-01 Novartis Ag Inhibidores de PI 3-quinasa y métodos para su uso
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
BRPI0810641A2 (pt) 2007-04-12 2019-09-24 Hoffmann La Roche "compostos farmacêuticos".
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
JP5539190B2 (ja) 2007-06-12 2014-07-02 エフ．ホフマン−ラ ロシュ アーゲー チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用
WO2009007748A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
EP2209786B1 (en) 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
ES2600919T3 (es) 2007-10-05 2017-02-13 Index Pharmaceuticals Ab Oligonucleótidos para el tratamiento o alivio de edema
KR20100083170A (ko) 2007-10-16 2010-07-21 와이어쓰 엘엘씨 티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 ｍＴＯＲ 키나제 및 ＰＩ3 키나제 억제제로서의 용도
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
JP5638955B2 (ja) 2007-10-26 2014-12-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
US20090149458A1 (en) 2007-11-27 2009-06-11 Wyeth PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
WO2009071895A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
GB0723747D0 (en) 2007-12-04 2008-12-31 Ucb Pharma Sa Therapeutic agents
WO2009071890A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
CN102014914A (zh) 2008-01-15 2011-04-13 惠氏有限责任公司 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US8557807B2 (en) 2008-01-24 2013-10-15 Signal Rx Pharmaceuticals, Inc. Thienopyranones as kinase inhibitors
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0906805A2 (pt) 2008-01-25 2015-07-14 Astrazeneca Ab Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use

Also Published As

Publication number Publication date
IL212278A0 (en) 2011-06-30
EP2336132B1 (en) 2014-01-01
CA2740471A1 (en) 2010-04-22
US20120071476A1 (en) 2012-03-22
US20100130492A1 (en) 2010-05-27
US8309546B2 (en) 2012-11-13
WO2010044401A1 (ja) 2010-04-22
NZ592761A (en) 2012-05-25
ZA201102449B (en) 2011-12-28
AU2009304789B2 (en) 2012-04-05
US8097622B2 (en) 2012-01-17
KR101614976B1 (ko) 2016-04-22
CO6362009A2 (es) 2012-01-20
CA2740471C (en) 2013-09-17
KR20110067038A (ko) 2011-06-20
HK1158189A1 (en) 2012-07-13
PL2336132T3 (pl) 2014-06-30
JP5090423B2 (ja) 2012-12-05
CN102245607A (zh) 2011-11-16
BRPI0920199A2 (pt) 2019-09-24
MX2011003490A (es) 2011-04-21
RU2490269C2 (ru) 2013-08-20
EP2336132A1 (en) 2011-06-22
TWI378933B (en) 2012-12-11
PT2336132E (pt) 2014-04-02
EP2336132A4 (en) 2012-03-21
AU2009304789A1 (en) 2010-04-22
IL212278A (en) 2016-07-31
RU2011119525A (ru) 2012-11-27
MY156456A (en) 2016-02-26
JP2011001339A (ja) 2011-01-06
DK2336132T3 (da) 2014-04-07
TW201018690A (en) 2010-05-16
ES2452541T3 (es) 2014-04-01

Similar Documents

Publication Publication Date Title
CN102245607B (zh) 吗啉代嘌呤衍生物
US12180215B2 (en) Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors
CN103313989B (zh) 三环pi3k抑制剂化合物和使用方法
TW202334138A (zh) 癌症治療方法
WO2023138583A1 (zh) 杂环类化合物、药物组合物及其应用
CN107995911A (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
EP2571884A2 (en) Mtor selective kinase inhibitors
RS59213B1 (sr) 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primena kao pi3k inhibitora
JP2011236198A (ja) モルホリノプリン誘導体
CN113004285A (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
CN119998295A (zh) 作为dgk抑制剂的三环三唑并化合物
DK3115365T3 (en) HIS UNKNOWN SALT OF CONDENSED PYRIMIDIDE COMPOUND AND CRYSTALS THEREOF
US20230201165A1 (en) Jak inhibitor compound for treating severe pneumonia
HK1158189B (en) Morpholinopurine derivative
HK1227874A1 (en) Tricyclic pi3k inhibitor compounds and methods of use
HK1227874A (en) Tricyclic pi3k inhibitor compounds and methods of use
HK1185871B (en) Tricyclic pi3k inhibitor compounds and methods of use
HK1227874B (en) Tricyclic pi3k inhibitor compounds and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140702

Termination date: 20171013